Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Parkinson's disease Stories

2013-06-17 16:25:52

First Implant of Company's Vercise Deep Brain Stimulation Device Designed to Treat Parkinson's NATICK, Mass., June 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the first implantation of its Vercise(TM) DBS System as part of the INTREPID clinical trial. INTREPID is a prospective, multi-center, double-blinded, randomized, controlled study to evaluate the safety and effectiveness of motor function and overall quality of life in patients with the Vercise...

2013-06-17 08:29:30

ATTEMPTS WORLD SKYDIVING RECORD TO BENEFIT FATHER WITH PARKINSON'S DISEASE MINNEAPOLIS, June 17, 2013 /PRNewswire-USNewswire/ -- Kevin Burkart will attempt a world skydiving record to benefit his father and all those living with Parkinson's on Wednesday, June 19, 2013. The event will be held from 5:00 a.m. until 11:00 p.m. at Skydive Twin Cities in Baldwin, WI. Burkart launched "100 Perfect Jumps for Parkinson's" in 2008 after his father was diagnosed with Parkinson's, a...

2013-06-15 23:01:55

Organic food advocate, Colle Farmers Market, responds to a Medical Daily article outlining how patients with Parkinson´s disease may benefit from eating food grown without pesticides. Bohemia, NY (PRWEB) June 15, 2013 On June 15, organic food advocate Colle Farmers Market issues a statement in response to a Medical Daily article, which details how organic food could prevent Parkinson´s disease. According to an article published by Medical Daily, some recent studies have suggested...

2013-06-13 08:28:04

NESS ZIONA, Israel, June 13, 2013 /PRNewswire/ -- NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study in healthy volunteers, and preliminary results from a phase IIA study in advanced Parkinson's patients, of ND0612, have been selected for presentation at the 17th International Congress of Parkinson's Disease and Movement Disorders, June 16th-20th in Sydney, Australia. ND0612 is a proprietary levodopa/carbidopa liquid drug formula under...

2013-06-10 08:30:20

Study Data to be Presented at 17th International Congress of Parkinson's Disease and Movement Disorders EMERYVILLE, Calif., June 10, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. announced today that the Company's Phase 2/3 EASED((TM)) (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia) clinical trial of ADS-5102 (Nurelin((TM)); amantadine HCl extended release) met the study's primary endpoint. ADS-5102 is an investigational...

2013-06-07 23:00:48

Latest Research in Movement Disorders to Be Presented at the MDS 17th International Congress of Parkinson´s Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013 Sydney (PRWEB) June 07, 2013 The world´s leading experts in Parkinson´s disease and Movement Disorders will present the latest research findings and state-of-the-art treatment options at The Movement Disorder Society´s 17th International Congress of Parkinson´s Disease and Movement Disorders...

2013-06-06 23:26:41

Research grants are awarded to scientists investigating essential tremor, a neurological movement disorder affecting more than 10 million Americans. Lenexa, KS (PRWEB) June 06, 2013 The International Essential Tremor Foundation (IETF) will fund three essential tremor (ET) research grants totaling nearly $85,000 this year. Grant funding was provided to the IETF from its own members, people directly affected by this life-altering neurological condition. “The IETF and Board of...

2013-06-04 16:24:32

NEW YORK, June 4, 2013 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has committed up to $10 million to its next funding round for the Edmond J. Safra Core Programs for PD Research to prioritize research toward transformative treatments and a cure for Parkinson's disease (PD). The Edmond J. Safra Core Programs include the Rapid Response Innovation Awards, focused on breakthrough ideas, Target Validation, which supports testing of biological targets...

2013-06-03 08:26:49

NESS ZIONA, Israel, June 3, 2013 /PRNewswire/ -- NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson's disease. These funds, part of the Foundation's 2013 Therapeutic Pipeline program, will support an upcoming phase 2 clinical trial with ND0612, a novel drug for the...

2013-05-31 23:14:14

Online Insurance Marketplace (http://www.onlineinsurancemarketplace.com), announces new blog, “Parkinson's disease and senior people!” (PRWEB) May 31, 2013 Online Insurance Marketplace has released a blog explaining the symptoms of Parkinson´s disease and why it is a necessary investment for senior people suffering from this disease! The blog mainly presents the symptoms of Parkinson´s disease. The most common symptom is uncontrollable shaking of a body part: arms,...